L
Laura Diane Porter
Publications - 6
Citations - 2729
Laura Diane Porter is an academic researcher. The author has contributed to research in topics: Medicine & Guideline. The author has an hindex of 1, co-authored 4 publications receiving 1557 citations.
Papers
More filters
Journal ArticleDOI
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer,Christina Lacchetti,Bryan J. Schneider,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marc S. Ernstoff,Jennifer M. Gardner,Pamela K. Ginex,Sigrun Hallmeyer,Jennifer Holter Chakrabarty,Natasha B. Leighl,Jennifer S. Mammen,David F. McDermott,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura Diane Porter,Igor Puzanov,Cristina A. Reichner,Bianca Santomasso,Carole Seigel,Alexander Spira,Maria E. Suarez-Almazor,Yinghong Wang,Jeffrey S. Weber,Jeffrey S. Weber,Jedd D. Wolchok,John A. Thompson +29 more
TL;DR: Recommendations for specific organ system-based toxicity diagnosis and management are presented and, in general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement.
Journal ArticleDOI
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Bryan J. Schneider,Jarushka Naidoo,Bianca Santomasso,Christina Lacchetti,Sherry Adkins,Milan J. Anadkat,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marianne Davies,M. S. Ernstoff,Leslie A. Fecher,Monalisa Ghosh,Ishmael Jaiyesimi,Jennifer S. Mammen,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura Diane Porter,Cristina A. Reichner,Carole Seigel,Jung-Min Song,Alexander I. Spira,Maria E. Suarez-Almazor,Umang Swami,John A. Thompson,Praveen Vikas,Yinghong Wang,Jeffrey S. Weber,Pauline Funchain,Kathryn Bollin +31 more
TL;DR: In this article, the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICP) was discussed. But, the authors did not provide guidance on recommended management.
Journal ArticleDOI
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Bianca Santomasso,Loretta J. Nastoupil,Sherry Adkins,Christina Lacchetti,Bryan J. Schneider,Milan J. Anadkat,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marianne Davies,M. S. Ernstoff,Leslie A. Fecher,Pauline Funchain,Ishmael Jaiyesimi,Jennifer S. Mammen,Jarushka Naidoo,Aung Naing,Tanyanika Phillips,Laura Diane Porter,Cristina A. Reichner,Carole Seigel,Jung-Min Song,Alexander I. Spira,Maria E. Suarez-Almazor,Umang Swami,John A. Thompson,Praveen Vikas,Yinghong Wang,Jeffrey S. Weber,Kathryn Bollin,Monalisa Ghosh +31 more
TL;DR: In this paper, the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) was discussed, with the aim to increase awareness, outline strategies, and offer guidance on the management of IRAEs.
Journal ArticleDOI
A delayed path to diagnosis: Findings from young-onset colorectal cancer patients and survivors.
TL;DR: There has been an increase in overall incidence and mortality among males and females in the US over the past decade, but the total number of patients diagnosed with CRC has not changed significantly.
editorialDOI
The Importance of Patient Engagement to Improve Healthcare Research and Safety
TL;DR: In this paper , the authors encourage preclinical researchers and patient partners to establish new collaborations, which may enhance research conduct in unique ways and should encourage pre-clinical researchers to seek new collaborations.